Skip to main content
Sultan Qaboos University Medical Journal logoLink to Sultan Qaboos University Medical Journal
. 2019 Mar 28;18(4):e529–e532. doi: 10.18295/squmj.2018.18.04.017

Lead Toxicity due to Ingestion of Lead-Contaminated Opium in a Patient Presenting with Motor Neuropathy and Upper Limb Paresis

A case report

Seyed M M Mirzaei 1, Ayob Akbari 2, Omid Mehrpour 3,*, Nasim Zamani 4
PMCID: PMC6443289  PMID: 30988975

Abstract

Opium users may present with central or peripheral nervous system-related symptoms, gastrointestinal complications and anaemia; in such cases, lead poisoning should be suspected and chelation therapy initiated as soon as possible. We report a 64-year-old male patient with a 20-year history of opium addiction who was referred to the Imam Reza Hospital, Birjand, Iran, in 2017 with severe motor neuropathy and paresis in both upper limbs. His primary symptoms were generalised weakness, abdominal and bone pain, constipation and lower limb paraesthesia that had started several months prior. In addition, he reported severe progressive bilateral paresis of the upper limbs of one month’s duration. A diagnosis of lead poisoning was confirmed by a blood lead level of 140 μg/dL. The patient underwent chelation therapy after which he improved significantly. At a one-year follow-up visit, he was neurologically intact and symptom-free.

Keywords: Opium Dependence, Lead Poisoning, Lead-Induced Nervous System Diseases, Paresthesia, Case Report, Iran


Exposure to certain toxic agents results in neurotoxicity which may lead to cognitive and memory disabilities, mood changes and even predispose the affected patient to psychiatric problems such as depression, anxiety and irritability.1 In factories producing glazed tiles, canned food, paint and cosmetics, workers may be affected by the presence of inorganic lead; in addition, drinking water and dust may be contaminated from industrial sources and motor vehicles.2,3 Another source of potential exposure is the presence of organic lead in opium.4,5 Lead may be intentionally added to the drug to increase its weight for profit-related reasons or it may be introduced accidentally during the production process.47 Subsequently, the lead is ingested by opium users either orally or via inhalation.6,8

In recent years, lead poisoning due to the ingestion of lead-contaminated opium has become a major health concern in Iran.49 According to Ghane et al., more than 4,000 patients with lead poisoning due to opium ingestion were referred in under one year to clinical centres in Iran with abdominal pain and constipation.10 Moreover, the researchers estimated that over 260,000 out of >700,000 opium users remained untreated and at risk of lead poisoning.10 This case report describes a patient who presented to Imam Reza Hospital, the main referral centre for poisoning cases in the South Khorasan province of Iran, with severe lead-induced motor neuropathy due to the ingestion of lead-contaminated opium.

Case Report

A 64-year-old male patient was referred to the Imam Reza Hospital, Birjand, in 2017 with generalised weakness, abdominal and bone pain, constipation and lower limb paraesthesia that had first started several months prior. The patient had then developed severe paresis in both upper limbs 30 days previously. He reported a 20-year history of oral opium use consisting of approximately 5 g daily. A urine drug analysis was positive for opium. Upon examination, the cranial nerves were normal, as were lower limb deep tendon reflexes; however, deep tendon reflexes in the upper limbs, biceps and triceps were absent. No sensory impairment was detected. The muscular power in the upper limbs was 2/5 and 1/5 in the proximal and distal areas, respectively, while the lower limbs were normal. The median and ulnar nerves were moderately affected, while the radial nerve was severely affected; the patient also had bilateral wrist drop.

Imaging studies yielded normal results, including brain and cervical magnetic resonance imaging (MRI), computed tomography (CT), a chest X-ray and abdominal ultrasonography. Brain CT and MRI scans revealed no evidence of a mass, haemorrhage, hydrocephalus or abnormalities in the basal ganglia and posterior fossa structures. No established infarct and intra- or extra-axial collections were detected in the major vessel vascular territory. The basal cisterns and foramen magnum were patent. The chest X-ray showed an increase in bilateral bronchovascular markings with no other abnormalities. Whole body bone scintigraphy was performed to rule out malignancy; this showed only minor tracer uptake throughout the skeleton. An endoscopy and colonoscopy revealed a 7-mm polypoid lesion in the D1–D2 junction of the duodenum and internal haemorrhoids in the anus. Electromyography confirmed chronic motor-sensory polyneuropathy with axonal features which were more severe in the upper limbs. Critically, the patient’s blood lead level was 140 μg/dL (normal range: <10 μg/dL). Table 1 shows the results of various other laboratory tests. Nerve conduction and F-wave parameters are shown in Tables 24.

Table 1.

Laboratory test results of a 64-year-old male opium addict with severe lead-induced motor neuropathy

Variable Result Normal range
White blood cell count in ×103/mm3 8.1 4–10
Haemoglobin in g/dL 9.6 14–18
Haematocrit in % 30.5 Males: 45–52
Females: 37–48
MCV in femtolitres 83.6 80–96
MCH count in pg 27.1 27–33
MCHC in % 32.5 32–36
Platelet count in ×103/mm3 206 150–450
Vitamin B12 in pg/mL 1,178 160–950
Folic acid in ng/mL 6 2–20
Serum iron in μg/dL 36.8 65–176
TIBC in μg/dL 176 240–450
Ferritin in ng/mL 338.9 12–300
Serum vitamin D in ng/mL 9.55 20–50
T3 in pg/mL 4 2.3–4.2
T4 in ng/dL 9.9 4.5–11.5
TSH in μIU/mL 0.5 0.5–4.7
T3RU in % 36.7 24–37
AST in U/L 50 <37
ALT in U/L 55 <41
Alkaline phosphatase in U/L 188 80–306
Total bilirubin in mg/dL 1.2 <1.1
Direct bilirubin in mg/dL 0.4 <0.6
Creatinine in mg/dL 1 0.5–1.4
Prothrombin time in seconds 13 10–13.5
Partial thromboplastin time in seconds 28 25–35
INR 1 <1.1
Wright agglutination test Negative Negative
2ME Negative Negative
ANAs Negative Negative
Rheumatoid factor Negative Negative
Anti-ds-DNA in IU/mL 2.37 <10
Serum albumin in g/dL 3.6 3.5–5
α-globulin in g/dL 0.2 0.1–0.3
α-2-globulin in g/dL 0.8 0.6–1
β-globulin in g/dL 0.7 0.7–1.2
γ-globulin in g/dL 1.1 0.7–1.6

MCV = mean corpuscular volume; MCH = mean cell haemoglobin; MCHC = mean corpuscular haemoglobin concentration; TIBC = total iron-binding capacity; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; T3RU = T3 resin uptake; AST = aspartate aminotransferase; ALT = alanine aminotransferase; INR = international normalised ratio; 2ME = 2-mercaptoethanol; ANAs = antinuclear antibodies; ds = double-stranded.

Table 2.

Motor nerve conduction parameters of a 64-year-old male opium addict with severe lead-induced motor neuropathy

Nerve and site/segment Latency in ms Amplitude in mV Distance in mm Velocity in m/s
Right median APB
Wrist 3.6 1.4 - -
Wrist-elbow 8.9 1.3 240 44.5
Left median APB
Wrist 3.3 1.0 - -
Wrist-elbow 8.2 0.959 240 39.3
Right ulnar ADM
Wrist 2.7 2.2 - -
Wrist-below elbow 7.0 1.9 260 40.8
Left ulnar ADM
Wrist 2.4 1.7 - -
Wrist-below elbow 7.1 1.5 260 39.4
Right radial EIP
Forearm Absent Absent - -
Elbow Absent Absent - -
Below spiral groove Absent Absent - -
Left radial EIP
Forearm Absent Absent - -
Elbow Absent Absent - -
Below spiral groove Absent Absent - -
Right DPN EDB
Ankle 3.5 1.8 - -
Ankle below FH 9.1 1.7 - -
Below FH-PF 9.8 1.8 350 41.3
Left DPN EDB
Ankle 5.1 1.8 - -
Ankle below FH 12.1 1.9 - -
Below FH-PF 12.8 1.8 340 38.4
Right tibial AHB
Medial ankle 6.3 3.1 - -
Medial ankle-PF 14.3 2.9 380 37.7
Left tibial AHB
Medial ankle 5.1 3.9 - -
Medial ankle-PF 13.6 4.3 380 44.3

APB = abductor pollicis brevis; ADM = abductor digiti minimi; EIP = extensor indicis proprius; DPN = deep peroneal nerve; EDB = extensor digitorum brevis; FH = fibula head; PF = popliteal fossa; AHB = abductor hallucis brevis.

Table 3.

Sensory nerve conduction parameters of a 64-year-old male opium addict with severe lead-induced motor neuropathy

Nerve Latency in ms Amplitude in uV Distance in mm Velocity in m/s
Right median 4.0 14.6 130 43.1
Left median 3.6 9.64 130 47.2
Right ulnar 3.8 16.9 110 51.4
Left ulnar 3.5 14.3 110 50.4
Right radial 3.3 13.1 90 56.4
Left radial 3.1 15.3 90 60.5
Right sural 3.1 3.55 - -
Left sural 2.7 3.0 - -

Table 4.

F-wave parameters of a 64-year-old male opium addict with severe lead-induced motor neuropathy

Nerve Latency in ms F/M amplitude in uVms F %
M F-M F min F max
Right median APB 4.3 24.2 28.6 31.1 0.11 50
Left median APB 3.7 22.0 25.7 32.1 0.14 60
Right ulnar ADM 0.1 28.2 28.3 33.0 0.07 100
Right tibial AHB 6.4 48.3 54.7 62.3 0.05 75
Left tibial AHB 0.1 54.1 54.2 54.7 0.03 66

min = minimum; max = maximum; APB = abductor pollicis brevis; ADM = abductor digiti minimi; HB = abductor hallucis brevis.

Based on his blood lead level, the patient was diagnosed with lead poisoning and admitted to hospital. He was initially treated with 4 mg/kg of dimercaprol via deep intramuscular injection every four hours, followed by 1,300 mg/day of intravenous calcium disodium (CaNa2) edetate four hours after the first dose of dimercaprol. After five days of parenteral treatment, his blood lead level was 60 μg/dL. He was discharged and prescribed 10 mg/kg of oral succimer, initially every eight hours for five days followed by every 12 hours for 14 days. After 21 days of treatment, his clinical symptoms began to improve, particularly the abdominal pain, generalised weakness and weakness in the upper limbs. However, at a three-month follow-up appointment, the patient reported that the upper limb weakness still persisted; moreover, his blood lead level was 44 μg/dL.

Due to a shortage of succimer, D-penicillamine treatment was initiated at a dose of 250 mg every eight hours for 10 days. After this, a neurological examination was normal, including examination of the power in the upper limbs, although the patient still complained of some upper limb weakness. He was referred to a rehabilitation clinic to undergo methadone maintenance therapy. One year later, his blood lead level was 20 μg/dL and the upper limb weakness had completely resolved.

Discussion

Symptoms of acute lead poisoning include nausea, headaches, cognitive problems and emotional impairment, while chronic lead exposure may cause fatigue, a decline in brain and cognitive function, motor impairment, psychiatric problems and, in some cases, a decline in nerve conduction velocity.11,12 Critically, initial symptoms of irritability, headache, fatigue, memory loss and tremors may progress to weakness, limb paralysis, seizures, delirium and hallucinations, coma and, eventually, death.13 As such, the early detection and immediate treatment of lead poisoning is imperative.

Neuropathy due to the ingestion of lead-contaminated opium is uncommon, with most patients presenting with anaemia and gastrointestinal symptoms.14,15 A combination of motor and sensory nervous system impairment, as seen in the current case, is even less common. Lead-induced neuropathy commonly affects the radial and peroneal nerves and extensor muscles, resulting in wrist and foot drop, while sensory processing disorders are less frequent.2,16 Beigmohammadi et al. reported a 40-year-old male oral opium addict who presented with weakness of the limbs due to severe lead poisoning (blood lead level: 200 μg/dL).17 The patient had digestive symptoms (including stomach aches and constipation) and severe weakness of the upper and lower limbs, although sensation was normal. Despite treatment with CaNa2 edetate, dimercaprol and oral succimer, the patient remained quadriplegic, although both his blood lead levels and gastrointestinal symptoms improved.17

Toxic-metabolic polyneuropathy may be induced by extrinsic or intrinsic metabolites which are toxic to the peripheral nerves, resulting in damage to the axial cylinders of the axons. The severity of this damage is dependent on the level of toxicity, duration of exposure and genetic characteristics of nervous tissue metabolism.18 Clinically, the damage manifests as both sensory impairment and muscle weakness, although muscle wasting and severe trophic disorders may also occur. In these cases, electroneuromyography would show a decrease in the amplitude of peripheral nerve sensory potentials and muscle action potential.18 In patients with axonal-type polyneuropathy, there is often sufficient retention of motor function—in the absence of severe paresis—while sensory and trophic impairments are disabling. Axonal nerve damage develops slowly and gradually, although it is potentially reversible with appropriate treatment.18

In the current case, the patient developed both motor and sensory neuropathy due to long-term exposure to high levels of lead. However, all neurological symptoms completely resolved after treatment with chelating agents. Most patients with sensory complications are resistant to treatment and a full recovery is not expected, even after chelation therapy.16 This case emphasises the importance of the timely diagnosis and treatment of cases of lead toxicity in order to reverse central and peripheral nervous system-related symptoms.

Conclusion

Opium addicts are predisposed to developing lead toxicity resulting from the ingestion of lead-contaminated opium. This may result in the development of serious symptoms such as cognitive, sensory and motor impairment, with delays in diagnosis and treatment potentially resulting in irreversible neurological damage. As such, lead poisoning should be suspected among opium users with central or peripheral nervous system-related symptoms, gastro-intestinal complications and anaemia. Chelation therapy should be initiated as soon as possible in such cases.

References

  • 1.Mason LH, Mathews MJ, Han DY. Neuropsychiatric symptom assessments in toxic exposure. Psychiatr Clin North Am. 2013;36:201–8. doi: 10.1016/j.psc.2013.02.001. [DOI] [PubMed] [Google Scholar]
  • 2.Gidlow DA. Lead toxicity. Occup Med (Lond) 2004;54:76–81. doi: 10.1093/occmed/kqh019. [DOI] [PubMed] [Google Scholar]
  • 3.Massadeh AM, El-Khateeb MY, Ibrahim SM. Evaluation of Cd, Cr, Cu, Ni, and Pb in selected cosmetic products from Jordanian, Sudanese, and Syrian markets. Public Health. 2017;149:130–7. doi: 10.1016/j.puhe.2017.03.015. [DOI] [PubMed] [Google Scholar]
  • 4.Ghaemi K, Ghoreishi A, Rabiee N, Alinejad S, Farzaneh E, Amirabadi Zadeh A, et al. Blood lead levels in asymptomatic opium addict patients: A case control study. Emerg (Tehran) 2017;5:e69. doi: 10.22037/emergency.v5i1.16636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hayatbakhsh MM, Oghabian Z, Conlon E, Nakhaee S, Amirabadizadeh AR, Zahedi MJ, et al. Lead poisoning among opium users in Iran: An emerging health hazard. Subst Abuse Treat Prev Policy. 2017;12:43. doi: 10.1186/s13011-017-0127-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mehrpour O, Karrari P, Abdollahi M. Chronic lead poisoning in Iran: A silent disease. Daru. 2012;20:8. doi: 10.1186/2008-2231-20-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Alinejad S, Aaseth J, Abdollahi M, Hassanian-Moghaddam H, Mehrpour O. Clinical aspects of opium adulterated with lead in Iran: A review. Basic Clin Pharmacol Toxicol. 2018;122:56–64. doi: 10.1111/bcpt.12855. [DOI] [PubMed] [Google Scholar]
  • 8.Karrari P, Mehrpour O, Abdollahi M. A systematic review on status of lead pollution and toxicity in Iran: Guidance for preventive measures. Daru. 2012;20:2. doi: 10.1186/1560-8115-20-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Dadpour B, Mehrpour O, Etemad L, Moshiri M. Lead poisoning-induced hypertensive crisis managed by prazosin: A case report. Iran Red Crescent Med J. 2013;15:526–8. doi: 10.5812/ircmj.4557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ghane T, Zamani N, Hassanian-Moghaddam H, Beyrami A, Noroozi A. Lead poisoning outbreak among opium users in the Islamic Republic of Iran, 2016-2017. Bull World Health Organ. 2018;96:165–72. doi: 10.2471/BLT.17.196287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dobbs MR, editor. Clinical Neurotoxicology: Syndromes, substances, environments. 1st ed. Philadelphia, Pennsylvania, USA: Saunders; 2009. pp. 259–72. [Google Scholar]
  • 12.Davis JM, Svendsgaard DJ. Nerve conduction velocity and lead: A critical review and meta-analysis. In: Johnson BL, editor. Advances in Neurobehavioral Toxicology: Applications in environmental and occupational health. 1st ed. Chelsea, Miami, USA: CRC Press; 1990. pp. 353–76. [Google Scholar]
  • 13.Mason LH, Harp JP, Han DY. Pb neurotoxicity: Neuropsychological effects of lead toxicity. Biomed Res Int. 2014;2014 doi: 10.1155/2014/840547. 840547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zamani N, Hassanian-Moghaddam H. Notes from the field: Lead contamination of opium - Iran, 2016. MMWR Morb Mortal Wkly Rep. 2018;66:1408–9. doi: 10.15585/mmwr.mm665152a4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.White LD, Cory-Slechta DA, Gilbert ME, Tiffany-Castiglioni E, Zawia NH, Virgolini M, et al. New and evolving concepts in the neurotoxicology of lead. Toxicol Appl Pharmacol. 2007;225:1–27. doi: 10.1016/j.taap.2007.08.001. [DOI] [PubMed] [Google Scholar]
  • 16.Moyer M. Metals in medicine and the environment: Peripheral neuropathy and metals. [Accessed: Jun 2018]. From: http://faculty.virginia.edu/metals/cases/moyer2.html.
  • 17.Beigmohammadi MT, Aghdashi M, Najafi A, Mojtahedzadeh M, Karvandian K. Quadriplegia due to lead-contaminated opium: Case report. Middle East J Anaesthesiol. 2008;19:1411–16. [PubMed] [Google Scholar]
  • 18.Kovrazhkina EA. [Axonal polyneuropathies: Pathogenesis and treatment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113:22–5. [PubMed] [Google Scholar]

Articles from Sultan Qaboos University Medical Journal are provided here courtesy of Sultan Qaboos University

RESOURCES